Resumen de Incatibant acetate treatment of angioedema induced by ACE inhibitors (Angiotensin-Conversion Enzyme inhibitors)
Tamara Pérez Robles, M. Ruano Encinar, María Teresa Caballero Molina, Carmen Gomez Traseira, Alicia Herrero Ambrosio
Angioedema, secondary to treatment with angiotensin-converting enzyme (ACE) inhibitor drugs, is a rare but potentially fatal adverse reaction. It is not related to dose or does not exist a temporary correlation between the ACEI intake and symptoms development. Bradykinin increased levels plays an important role in triggering mechanism. This type of angioedema, as happens with the hereditary ones, responds poorly to usual treatment of histamine-mediated edema. Icatibant acetate was commercialized in Spain in 2009 for the symptomatic treatment of acute attacks related to hereditary angioedema in adults with C1 esterase inhibitor deficiency. It is a selective competitive bradykinin 2 receptor antagonist and its action mechanism makes it promising for angioedema secondary to ACEI. We described a case in which icatibant acetate was used off-label in angioedema secondary to ACEI where rapid symptoms of improvement after administration were obtained
